Cargando…
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?
BACKGROUND: The aims of this research were to provide a better understanding of the specific evidence needs for assessment of clinical and cost-effectiveness of cell and gene therapies, and to explore the extent that the relevant categories of evidence are considered in health technology assessment...
Autores principales: | Drummond, Michael, Ciani, Oriana, Fornaro, Giulia, Jommi, Claudio, Dietrich, Eva Susanne, Espin, Jaime, Mossman, Jean, de Pouvourville, Gerard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182681/ https://www.ncbi.nlm.nih.gov/pubmed/37179322 http://dx.doi.org/10.1186/s12913-023-09494-5 |
Ejemplares similares
-
The role of health technology assessment bodies in shaping drug development
por: Ciani, Oriana, et al.
Publicado: (2014) -
Unlocking the potential of established products: toward new incentives rewarding innovation in Europe
por: Nayroles, Gabrielle, et al.
Publicado: (2017) -
How innovation can be defined, evaluated and rewarded in health technology assessment
por: Rejon-Parrilla, Juan Carlos, et al.
Publicado: (2022) -
EQ-5D-5L Population Norms for Italy
por: Meregaglia, Michela, et al.
Publicado: (2022) -
Editorial: Near-infrared fluorescence guided surgery: State of the evidence from a health technology assessment perspective
por: Bertolaccini, Luca, et al.
Publicado: (2023)